top of page
책의 스택

Publications

Key Publications

*: First author
†: Corresponding author

  1. Lee SH*†, ..., Cho BC. Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA. Journal of Thracic Oncology. 2025.

  2. Kang J*, Lee JH*, Cha H, …, Lee SH†, Choi JK†, Park JE†. Systematic dissection of tumor-normal single-cell ecosystems across a thousand tumors of 30 cancer types. Nature Communications. 2024.

  3. Kim JY*, Cha H, …, Cho DY†, Lee SH†, Choi JK†. MHC II immunogenicity shapes the neoepitope landscape in human tumors. Nature Genetics. 2023.

  4. Ng KW*, Boumelha J*, Enfield KSS*, Cha H, ..., Kim H, Shim S, ..., Lee SH, ..., Swanton C†, Downward J†, Kassiotis G†. Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature. 2023.

  5. Hill W*, Lim EL*, Weeden CE*, ..., Lee SH, ..., Swanton C†. Lung adenocarcinoma promotion by air pollutants. Nature. 2023.

  6. Hong TH*, Bang YH*, Joe CY, ..., Lee NE, ..., Lee SH†. Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC. Journal of Thoracic Oncology. 2023.

  7. Lee SH*, Kim Y*, Jeon BN*, Kim G*, …, Kim H, Cha H, Lee NE, …, Park H†, Yoon KW†. Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8+ T Cells. Advanced Science. 2023.

  8. Roh W*, Geffen Y*, Cha H, …, Lee SH†, Getz G†. High-resolution profiling of lung adenocarcinoma identifies expression subtypes with specific biomarkers and clinically relevant vulnerabilities. Cancer Research. 2022.

  9. Park S*, Ock CY*, Kim H*, …, Cha H, …, Choi YL†, Mok TS†, Lee SH†. Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 2022.

  10. Lee SH*, Cho SY*, Yoon Y*, Park C*, …, Kim HS, …, Yoon KW†, Park H†. Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. Nature Microbiology. 2021.

  11. Lee JS*†, ..., Lee SH, ..., Ruppin E†. Synthetic lethality-mediated precision oncology via the tumor transcriptome. Cell. 2021.

  12. Litchfield K*, Reading JL*, Puttick C*, ..., Lee SH, ..., Quezada SA†, McGranahan N†, Swanton C†. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021.

  13. Shim JH*, Kim HS*, Cha H*, …, Park WY†, Lee SH†. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. Annals of Oncology. 2020.

All Publications

2025

  • Kim J*†, Bang YH*, …, Lee SH†. Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoma with micropapillary or solid histological subtypes: a single-center, single-arm, phase 2 trial. eClinicalMedicine. 2025.

  • Sim H*, Park GH*, Park WY, Lee SH†. Choi M†. Single‐cell‐eQTL mapping in circulating immune cells reveals genetic regulation of response‐associated networks in lung cancer immunotherapy. Cancer Communications. 2025.

  • Lee SH*†, …, Cho BC. Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA. Journal of Thoracic Oncology. 2025.

  • Park GH*, Park S*, Kim H, …, Lee SH†. Prospective investigation of biomarker and resistance mechanism using longitudinal cell-free NGS in non-small cell lung cancer with EGFR exon 20 insertion treated with amivantamab. European Journal of Cancer. 2025.

  • Jeong DY*, Joe CY*, Lee SM*, Park S, …, Lee SH†, Lee HY†. Unraveling the tumor-microenvironment through a radiogenomic-based multiomic approach to predict outcomes of immunotherapy in non-small cell lung cancer. Computer Methods and Programs in Biomedicine. 2025.

2024

  • Park S*, Kang JK*, Lee NE*, Lee SH†, …, Kim H, …, Park K. Predicting disease recurrence in limited disease small cell lung cancer using cell-free DNA-based mutation and fragmentome analyses. Translational Lung Cancer Research. 2024.

  • Park S*, Hong TH*, Hwang S*, …, Kim J, …, Choi YL†, Lee SH†, Park K†. Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer. EBioMedicine. 2024.

  • Kang J*, Lee JH*, Cha H, …, Lee SH†, Choi JK†, Park JE†. Systematic dissection of tumor-normal single-cell ecosystems across a thousand tumors of 30 cancer types. Nature Communications. 2024.

  • Lee K*, Cha H*, …, Joe CY, …, Lee SH†, Lee S†. Dissecting transcriptome signals of anti-PD-1 response in lung adenocarcinoma. Scientific Reports. 2024.

  • Lee SH*, Kim S*, Lee J*, Kim Y*, Joo Y, Heo JY, …, Hwang GS†, Park H†. Comprehensive metabolomic analysis identifies key biomarkers and modulators of immunotherapy response in NSCLC patients. Drug Resistance Updates. 2024.

  • Sim H*, Park HJ*, Park GH*, …, Lee SH†, Choi M†. Increased inflammatory signature in myeloid cells of non-small cell lung cancer patients with high clonal hematopoiesis burden. eLife. 2024.

2023

  • Kim JY*, Cha H, …, Cho DY†, Lee SH†, Choi JK†. MHC II immunogenicity shapes the neoepitope landscape in human tumors. Nature Genetics. 2023.

  • Kim H*, Park S*, Han KY, Lee NE, Kim H, …, Lee SH†, Park WY†. Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment. Journal for ImmunoTherapy of Cancer. 2023.

  • Jeon Y*, …, Lee SH†. Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement. Cancer Research and Treatement. 2023.

  • Lee SH*, Kim Y*, Jeon BN*, Kim G*, …, Kim H, Cha H, Lee NE, …, Park H†, Yoon KW†. Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8+ T Cells. Advanced Science. 2023.

  • Hong TH*, Bang YH*, Joe CY, …, Lee NE, …, Lee SH†. Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC. Journal for ImmunoTherapy of Cancer. 2023.

  • Choi SW*, Jung HA*, …, Nam DH#, Lee SH†. A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification. Cancer Medicine. 2023.

  • Choi DH*, …, Lee SH†. Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC). Translational Lung Cancer Research. 2023.

2022

  • Lee YP*, Jung HA*, …, Lee JI†, Lee SH†. Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma. Journal of NeuroOncology. 2022.

  • Park S*, Ock CY*, Kim H*, …, Cha H, …, Choi YL†, Mok TS†, Lee SH†. Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 2022.

  • Jeong H*, Lee H*, Kim H*, …, Kim HS, Lee NE, Lee YM, …, Lee S†, Lee SH†. Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma. iScience. 2022.

  • Roh W*, Geffen Y*, Cha H, …, Lee SH†, Getz G†. High-resolution profiling of lung adenocarcinoma identifies expression subtypes with specific biomarkers and clinically relevant vulnerabilities. Cancer Research. 2022.

  • Park S*, Cha H*, Kim HS*, …, Lee SH†. Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma. Cancer Medicine. 2022.

2021

  • Hwang S*, Hong TH*, Park S*, ..., Choi YL†, Lee SH†. Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment. Translational Lung Cancer Research. 2021.

  • Park JG*, ..., Lee SH†, Yoo BC†. Plasma complement C7 as a target in non-small cell lung cancer patients to implement 3P medicine strategies. EPMA Journal. 2021.

  • Lee SH*, Cho SY*, Yoon Y*, Park C*, …, Kim HS, …, Yoon KW†, Park H†. Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. Nature Microbiology. 2021.

2020

  • ​Kim JY*, Jeong HO*, ..., Lee S†, Lee SH†. Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data. Annals of Translational Medicine. 2020.

  • Hong TH*, Cha H*, Shim JH*, ..., Lee Y, ..., Lee SH†, Park WY†. Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. Journal for ImmunoTherapy of Cancer. 2020.

  • Kim G*, Kim J*, Cha H, ..., Lee SH†, Moon SH†. Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations. Scientific Reports. 2020.

  • Lee J*, Kim HS*, ..., Park K†, Lee SH†. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non–small cell lung cancer. Cancer. 2020.

  • Shim JH*, Kim HS*, Cha H*, …, Park WY†, Lee SH†. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. Annals of Oncology. 2020.

  • Kim K*, Kim HS*, ..., Lee SH†, Choi JK†. Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. Nature Communications. 2020.

  • Park S*, Shim J*, ..., Lee SH†, Park K†. Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy. Cancer. 2020.

2019

  • Im Y*, ..., Jhun BW​†, Lee SH†. Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors. Respiratory Medicine. 2019.

  • Byeon S*, ..., Lee SH†. Benefit of Targeted DNA Sequencing in Advanced Non–Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. Clinical Lung Cancer. 2019.

  • Jung H*, Kim HS*, ..., Lee SH†, Choi JK†. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nature Communications. 2019.

  • Kim HS*, Cha H*, ..., Lee SH†. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. European Journal of Cancer. 2019.

  • Shin SH*, Park HY*, Im Y*, ..., Lee SH†. Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. International Journal of Cancer. 2019.

  • Keam B*, Lee KW†, Lee SH†, ..., Heo DS. A Phase II Study of Genexol‐PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. The Oncologist. 2019.

bottom of page